Ipsen S.A. ADR (OP: IPSEY )
29.94 -0.23 (-0.76%) Streaming Delayed Price Updated: 10:33 AM EDT, May 26, 2023 Add to My Watchlist
All News about Ipsen S.A. ADR
What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur
May 22, 2023
On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid...
Genfit To Buy This Swiss Firm Expanding Its Portfolio in Liver Diseases
September 19, 2022
Why Merrimack Shares Are Surging Over 200% Today?
November 09, 2022
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...
Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting
October 25, 2022
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
October 02, 2022
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following